Embecta Shareholder Files Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
Source: Globenewswire
- Lawsuit Background: Bernstein Liebhard LLP announced that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased Embecta Corp. stock between November 25, 2025, and May 4, 2026, alleging significant false statements regarding the company's operations and financial stability.
- Investor Action Recommendation: Investors are encouraged to promptly submit a form to participate in the lawsuit, and those wishing to serve as lead plaintiff must file papers by August 17, 2026; absent members may not share in any recovery if they choose not to act.
- Loss Impact: The lawsuit claims that due to the company's alleged misrepresentations, Embecta's stock traded at artificially inflated prices during the class period, leading to significant losses for investors when the truth was revealed, indicating potential financial and reputational risks for the company.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, showcasing its strong capabilities in securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Lawsuit Background: Bleichmar Fonti & Auld LLP has announced a class action lawsuit against Embecta Corp and its executives for securities fraud, resulting in a significant stock drop that severely undermines investor confidence in the company's future prospects.
- Stock Price Plunge: On May 5, 2026, Embecta's Q2 results fell short of expectations, causing its stock price to plummet from $9.25 to $3.90, a staggering 57.8% drop, which not only erodes investor value but may also complicate the company's future financing efforts.
- Competitive Market Pressure: The lawsuit highlights that Embecta's insulin pen product line, previously touted as strong, is actually facing significant competition and overall market softness, indicating a misalignment in the company's market strategy and execution.
- Dividend Cut: Due to disappointing performance, Embecta slashed its quarterly dividend from $0.15 to $0.01, reflecting cash flow challenges that could hinder future investments and growth plans, further eroding investor confidence.
See More
- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit following its disastrous Q2 2026 earnings report, which has raised significant concerns about the company's credibility among investors who purchased shares between November 25, 2025, and May 4, 2026.
- Performance Decline: The company reported an adjusted EPS of only $0.27 for Q2 2026, representing a staggering 61% year-over-year decline, starkly contrasting with its previous guidance of $2.80 to $3.00 for the year, leading to a substantial loss of investor confidence.
- Dividend Cut: Embecta slashed its 2026 adjusted EPS guidance to $1.55 to $1.75 and reduced its dividend by 93% to just $0.01, highlighting severe challenges in its core pen needle market and the impact on shareholder returns.
- Market Reaction: The stock experienced a significant selloff as the management failed to adequately communicate potential risks, with analysts emphasizing the need for the company to rebuild investor trust in its commercial execution and profitability outlook, indicating uncertainty in its future growth prospects.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased common stock of Embecta Corp. between November 25, 2025, and May 4, 2026, to apply as lead plaintiff by August 17, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, particularly in its 2026 fiscal guidance, leading to investor losses when the true situation was revealed, thereby impacting the company's market credibility.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record, urging investors to choose experienced legal counsel wisely.
- Investor Rights Protection: Until the class action is certified, investors can choose to remain absent or hire counsel, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff, ensuring all investors have the opportunity to participate in potential compensation.
See More
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Embecta, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by August 17, 2026.
- Disappointing Earnings: Embecta's Q2 2026 financial results revealed a revenue decline of over 14%, significantly worse than the guidance of flat to a 2% decline, primarily due to weak pen needle sales, prompting a downward revision of fiscal year 2026 estimates.
- Stock Price Plunge: Following the disappointing earnings report, Embecta's stock price plummeted nearly 58%, causing substantial losses for investors and reflecting a pessimistic outlook on the company's future performance.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class litigation, has a long history of recovering multimillion-dollar damages for victims of securities fraud, underscoring its commitment to protecting investor rights.
See More
- Declining Financial Performance: Embecta reported a more than 14% revenue decline in its Q2 2026 financial results, primarily due to weak pen needle sales, which led the company to lower its guidance for the fiscal year 2026, directly impacting investor confidence.
- Stock Price Plunge: Following the earnings report on May 5, 2026, Embecta's stock price fell by $5.35, a staggering 57.8% drop, closing at $3.90 per share, resulting in significant losses for investors.
- Class Action Context: The class action lawsuit against Embecta alleges that the company made materially false statements and failed to disclose adverse facts about its business and prospects during the class period, severely undermining investor trust in the company's future.
- Legal Action Deadline: Investors must file a lead plaintiff motion by August 17, 2026, to participate in the class action lawsuit and seek recovery for their investment losses, ensuring their legal rights are protected.
See More
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Embecta Corp. and its officers, alleging violations of federal securities laws from November 25, 2025, to May 4, 2026, seeking damages for affected investors.
- Misleading Performance Claims: The complaint alleges that Embecta misrepresented its pen needle business as 'incredibly resolute' just weeks before failing to meet second-quarter 2026 expectations, leading to a significant loss of investor confidence.
- Significant Revenue Decline: Embecta reported a revenue drop of over 14%, far exceeding the guidance of flat to a 2% decline, indicating severe weaknesses in its U.S. performance, particularly in pen needle sales.
- Investor Rights Protection: Investors have until August 17, 2026, to apply as lead plaintiffs, with Bronstein's firm offering legal representation on a contingency fee basis, ensuring that investor rights are upheld and potential recoveries are pursued.
See More











